Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chong-Jen Yu

Showing results (411-420 of 478) with videos related to

Pageof 48
Sort By:
Cancer Science|January 29, 2026
Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52Jong-Seok Lee, Shunichi Sugawara, Jin-Hyoung Kang, et al.
Lung Cancer (Amsterdam, Netherlands)|February 2, 2025
First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trialKi Hyeong Lee, Jong-Seok Lee, Shunichi Sugawara, et al.
Scientific Reports|May 21, 2017
Significant Clinical Factors Associated with Long-term Mortality in Critical Cancer Patients Requiring Prolonged Mechanical VentilationLi-Ta Keng, Kuei-Pin Chung, Shu-Yung Lin, et al.
Sleep|August 28, 2025
CPAP Effects on Energy Expenditure, Intake, Hormonal Regulation, and Body Composition: A Randomized TrialPei-Lin Lee, Meng-Yueh Chien, Shang-Ru Lai, et al.
Japanese Journal of Clinical Oncology|December 5, 2006
Revisit of 1997 TNM staging system--survival analysis of 1112 lung cancer patients in TaiwanReury-Perng Perng, Chih-Yi Chen, Gee-Chen Chang, et al.
Clinical and Translational Medicine|December 23, 2024
Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysisShang-Gin Wu, Chao-Chi Ho, James Chih-Hsin Yang, et al.
Oncology|October 1, 2023
Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint InhibitorsDerek De-Rui Huang, Bin-Chi Liao, Wei-Hsun Hsu, et al.
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|January 23, 2023
Outbreak investigation in a COVID-19 designated hospital: The combination of phylogenetic analysis and field epidemiology study suggesting airborne transmissionYi-Chia Huang, Hsiao-Chen Tu, Han-Yueh Kuo, et al.
International Journal of Chronic Obstructive Pulmonary Disease|October 27, 2021
Effectiveness of Nationwide COPD Pay-for-Performance Program on COPD Exacerbations in TaiwanShih-Lung Cheng, Yi-Rong Li, Nicole Huang, et al.
Nature Medicine|June 19, 2024
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trialSolange Peters, Shirish M Gadgeel, Tony Mok, et al.
Pageof 48

Showing results (411-420 of 478) with videos related to

Sort By:
Pageof 48
Cancer Science|January 29, 2026
Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52Jong-Seok Lee, Shunichi Sugawara, Jin-Hyoung Kang, et al.
Lung Cancer (Amsterdam, Netherlands)|February 2, 2025
First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trialKi Hyeong Lee, Jong-Seok Lee, Shunichi Sugawara, et al.
Scientific Reports|May 21, 2017
Significant Clinical Factors Associated with Long-term Mortality in Critical Cancer Patients Requiring Prolonged Mechanical VentilationLi-Ta Keng, Kuei-Pin Chung, Shu-Yung Lin, et al.
Sleep|August 28, 2025
CPAP Effects on Energy Expenditure, Intake, Hormonal Regulation, and Body Composition: A Randomized TrialPei-Lin Lee, Meng-Yueh Chien, Shang-Ru Lai, et al.
Japanese Journal of Clinical Oncology|December 5, 2006
Revisit of 1997 TNM staging system--survival analysis of 1112 lung cancer patients in TaiwanReury-Perng Perng, Chih-Yi Chen, Gee-Chen Chang, et al.
Clinical and Translational Medicine|December 23, 2024
Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysisShang-Gin Wu, Chao-Chi Ho, James Chih-Hsin Yang, et al.
Oncology|October 1, 2023
Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint InhibitorsDerek De-Rui Huang, Bin-Chi Liao, Wei-Hsun Hsu, et al.
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|January 23, 2023
Outbreak investigation in a COVID-19 designated hospital: The combination of phylogenetic analysis and field epidemiology study suggesting airborne transmissionYi-Chia Huang, Hsiao-Chen Tu, Han-Yueh Kuo, et al.
International Journal of Chronic Obstructive Pulmonary Disease|October 27, 2021
Effectiveness of Nationwide COPD Pay-for-Performance Program on COPD Exacerbations in TaiwanShih-Lung Cheng, Yi-Rong Li, Nicole Huang, et al.
Nature Medicine|June 19, 2024
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trialSolange Peters, Shirish M Gadgeel, Tony Mok, et al.
Pageof 48